Katrin Sproesser

4.5k total citations · 1 hit paper
16 papers, 1.2k citations indexed

About

Katrin Sproesser is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Katrin Sproesser has authored 16 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Immunology. Recurrent topics in Katrin Sproesser's work include Melanoma and MAPK Pathways (6 papers), Immunotherapy and Immune Responses (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Katrin Sproesser is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), Immunotherapy and Immune Responses (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Katrin Sproesser collaborates with scholars based in United States, Australia and Mali. Katrin Sproesser's co-authors include Meenhard Herlyn, Katherine L. Nathanson, Patricia Brafford, Clemens Krepler, Min Xiao, Stefan Torborg, Benjamin Emert, Ioannis N. Anastopoulos, Sydney M. Shaffer and Marilda Beqiri and has published in prestigious journals such as Nature, The Journal of Immunology and Cancer Research.

In The Last Decade

Katrin Sproesser

15 papers receiving 1.2k citations

Hit Papers

Rare cell variability and drug-induced reprogramming as a... 2017 2026 2020 2023 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
    2017 756 citations Sydney M. Shaffer, Margaret C. Dunagin et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katrin Sproesser United States 8 935 450 223 180 121 16 1.2k
Marilda Beqiri United States 5 658 0.7× 354 0.8× 211 0.9× 153 0.8× 77 0.6× 6 945
Marco Piva United States 10 748 0.8× 616 1.4× 202 0.9× 214 1.2× 92 0.8× 13 1.1k
Anne Margriet Heijink Netherlands 12 896 1.0× 412 0.9× 141 0.6× 114 0.6× 138 1.1× 13 1.2k
David Twomey United States 5 1.1k 1.2× 418 0.9× 242 1.1× 195 1.1× 81 0.7× 7 1.6k
Vito W. Rebecca United States 18 1.0k 1.1× 668 1.5× 123 0.6× 228 1.3× 152 1.3× 28 1.4k
Bjoern Papke Germany 9 1.0k 1.1× 346 0.8× 122 0.5× 64 0.4× 215 1.8× 12 1.2k
Sareena Rana United Kingdom 15 1.1k 1.2× 821 1.8× 212 1.0× 335 1.9× 185 1.5× 24 1.7k
Ella Kim Germany 21 833 0.9× 607 1.3× 206 0.9× 62 0.3× 51 0.4× 38 1.2k
Anil Korkut United States 14 704 0.8× 368 0.8× 302 1.4× 58 0.3× 49 0.4× 28 1.1k
Michal Barzily-Rokni Israel 3 1.2k 1.2× 937 2.1× 327 1.5× 284 1.6× 211 1.7× 4 1.8k

Countries citing papers authored by Katrin Sproesser

Since Specialization
Citations

This map shows the geographic impact of Katrin Sproesser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katrin Sproesser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katrin Sproesser more than expected).

Fields of papers citing papers by Katrin Sproesser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katrin Sproesser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katrin Sproesser. The network helps show where Katrin Sproesser may publish in the future.

Co-authorship network of co-authors of Katrin Sproesser

This figure shows the co-authorship network connecting the top 25 collaborators of Katrin Sproesser. A scholar is included among the top collaborators of Katrin Sproesser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katrin Sproesser. Katrin Sproesser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Smans, Karine, Katrin Sproesser, Kathryn Packman, et al.. (2024). 144 (PB132): JNJ-79032421 is a novel membrane restricted mesothelin targeting Tcell engaging bispecific antibody for treatment of mesothelin-positive cancers. European Journal of Cancer. 211. 114666–114666.
2.
Basu, Subhasree, Mike R. Russell, Katrin Sproesser, et al.. (2022). Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models. Cancer Research. 82(12_Supplement). LB087–LB087. 1 indexed citations
3.
Diem, Michael, Weirong Wang, Robert Schulingkamp, et al.. (2020). Abstract 5662: JNJ-67571244: A novel anti-CD33 C2 domain binding bispecific antibody with potent T cell redirection activity. Cancer Research. 80(16_Supplement). 5662–5662. 1 indexed citations
4.
Diem, Michael, Weirong Wang, Robert Schulingkamp, et al.. (2020). A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Advances. 4(5). 906–919. 35 indexed citations
5.
Hammerlindl, Heinz, Dinoop Ravindran Menon, Abdullah Al Emran, et al.. (2017). Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS -Mutant Cancers. Clinical Cancer Research. 24(5). 1090–1102. 15 indexed citations
6.
Shaffer, Sydney M., Margaret C. Dunagin, Stefan Torborg, et al.. (2017). Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 546(7658). 431–435. 756 indexed citations breakdown →
7.
Fatkhutdinov, Nail, Katrin Sproesser, Clemens Krepler, et al.. (2016). Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Molecular Cancer Research. 14(9). 767–775. 23 indexed citations
8.
Brafford, Patricia & Katrin Sproesser. (2016). 1205Lu is Human Melanoma Depending on the Source. Journal of Cancer Science & Therapy. 8(5). 2 indexed citations
9.
Slipicevic, Ana, Rajasekharan Somasundaram, Katrin Sproesser, & Meenhard Herlyn. (2013). Isolation of Melanoma Cell Subpopulations Using Negative Selection. Methods in molecular biology. 1102. 501–512. 4 indexed citations
10.
Lee, John Tayu, Ling Li, Patricia Brafford, et al.. (2010). PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas. Pigment Cell & Melanoma Research. 23(6). 820–827. 124 indexed citations
11.
Haass, Nikolas K., Katrin Sproesser, Thiennga K. Nguyen, et al.. (2008). The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel. Clinical Cancer Research. 14(1). 230–239. 185 indexed citations
12.
Haass, Nikolas K., et al.. (2007). The novel MEK1/2 inhibitor AZD6244 (ARRY-142886) inhibits the growth of melanomas harboring the BRAF V600E mutation in vitro and in vivo. Queensland's institutional digital repository (The University of Queensland). 127. 2 indexed citations
13.
Wondimu, Assefa, Tianqian Zhang, Thomas Kieber‐Emmons, et al.. (2007). Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunology Immunotherapy. 57(7). 1079–1089. 34 indexed citations
14.
Haass, Nikolas K., Keiran S.M. Smalley, Rooha Contractor, Katrin Sproesser, & Meenhard Herlyn. (2006). The novel MEK inhibitor AZD6244/ARRY142886 inhibits the growth of melanomas harboring the BRAFV600E mutation in vitro and in vivo. Melanoma Research. 16(Supplement 1). S92–S93. 3 indexed citations
15.
Li, Jian, Weiping Li, Shaohong Liang, et al.. (2003). Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice. The Journal of Immunology. 171(6). 2922–2929. 3 indexed citations
16.
Basak, Saroj K., Brigitte Birebent, Enkhtsetseg Purev, et al.. (2003). Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunology Immunotherapy. 52(3). 145–154. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marilda Beqiri Breakdown of academic impact, for papers by Marco Piva Breakdown of academic impact, for papers by Anne Margriet Heijink Breakdown of academic impact, for papers by David Twomey Breakdown of academic impact, for papers by Vito W. Rebecca Breakdown of academic impact, for papers by Bjoern Papke Breakdown of academic impact, for papers by Sareena Rana Breakdown of academic impact, for papers by Ella Kim Breakdown of academic impact, for papers by Anil Korkut Breakdown of academic impact, for papers by Michal Barzily-Rokni
Rankless by CCL
2026